Rosetta Genomics Ltd. and Super Religare Laboratories Limited (SRL) Announce Exclusive Distribution Agreement for Rosetta’s MicroRNA-based Assays in India, Saudi Arabia, Qatar, and the United Arab Emirates (UAE)

PHILADELPHIA & NEW DELHI--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ:ROSG), a leading developer of microRNA-based molecular diagnostics, and Super Religare Laboratories Limited (SRL), India’s largest diagnostics network, announced today that they have signed an exclusive distribution agreement for Rosetta Genomics’ three currently-available diagnostic tests. Under the terms of the agreement, SRL will market Rosetta Genomics’ miRview™ tests in India, Saudi Arabia, Qatar, and the UAE. Samples will be sent from SRL’s territories to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis. The terms of the deal were not disclosed.

MORE ON THIS TOPIC